ELI LILLY AND COMPANY Operating Lease Right-of-Use Assets
ELI LILLY AND COMPANY (LLY) had Operating Lease Right-of-Use Assets of $1.26 billion as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-02-12
- 2025-12-31: Operating Lease, Right-of-Use Asset $1.26B.
- 2024-12-31: Operating Lease, Right-of-Use Asset $1.05B; Operating Lease, Right-of-Use Asset as first filed $1.05B.
- 2023-12-31: Operating Lease, Right-of-Use Asset $1.02B.
- 2019-12-31: Operating Lease, Right-of-Use Asset $532.10M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2025-12-31 | $1.26B 10-K · filed 2026-02-12 | |
| 2024-12-31 | $1.05B 10-K · filed 2026-02-12 | $1.05B 10-K · filed 2025-02-19 |
| 2023-12-31 | $1.02B 10-K · filed 2025-02-19 | |
| 2019-12-31 | $532.10M 10-K · filed 2020-02-19 | |
| 2019-09-30 | $535.70M 10-Q · filed 2019-10-25 | |
| 2019-06-30 | $545.50M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $546.50M 10-Q · filed 2019-05-02 | |
| 2019-01-01 | $530.00M 10-K · filed 2021-02-17 | |
| 2018-12-31 | $0.00 10-Q · filed 2019-10-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |